Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Atrial Fibrillation - Pipeline Insight, 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
It report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial Fibrillation pipeline landscape is provided which includes the disease overview and Atrial Fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial Fibrillation commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.
Atrial Fibrillation Emerging Drugs Chapters
This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atrial Fibrillation Emerging Drugs
Milvexian: Bristol-Myers Squibb
Milvexian (BMS-986177) is an investigational, oral factor XIa (FXIa) inhibitor being studied for the prevention and treatment of major thrombotic conditions, including ischemic stroke, acute coronary syndrome, atrial fibrillation, atrial flutter, and venous thromboembolism. It is administered through oral routes as a suspension, tablets, and capsules. Milvexian acts by targeting FXIa, a cofactor that plays a crucial role in the coagulation cascade. The Librexia program, which is the most comprehensive FXIa clinical development program to date, is evaluating milvexian in three parallel clinical trials (Librexia STROKE, Librexia ACS, and Librexia AF). Currently, the drug is in Phase III stage of its clinical trial for the treatment of atrial fibrillation.
Etripamil: Milestone Pharmaceuticals
Etripamil is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. The drug is in Phase III clinical studies for the treatment of paroxysmal supraventricular tachycardia and in Phase II clinical studies to treat atrial fibrillation.
AP31969: Acesion Pharma
AP31969 is a second-generation oral SK channel inhibitor being developed by Acesion Pharma for chronic oral maintenance treatment to prevent AF recurrence. The drug has demonstrated a low risk of proarrhythmia in pre-clinical studies, with no prolongations of the corrected QT interval in two in-vivo large animal models. AP31969 also has good oral pharmacokinetic properties and a low risk of causing drug-drug interactions. Currently, the drug is in Phase I stage of its clinical trial for the treatment of atrial fibrillation.
Atrial Fibrillation: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.
Key Questions
- How many companies are developing Atrial Fibrillation drugs?
- How many Atrial Fibrillation drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atrial Fibrillation and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Omeicos Therapeutics
- HUYABIO International
- Acesion Pharma
- Bristol-Myers Squibb
- Anthos Therapeutic
- Milestone Pharmaceuticals
- ARCA biopharma
- Thryv Therapeutics
Key Products
- OMT-28
- HBI-3000
- AP31969
- Milvexian
- Abelacimab
- Etripamil
- Bucindolol
- LQT-1268
Major Players in Atrial Fibrillation
- There are approx. 12+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Atrial Fibrillation Report Insights
- Atrial Fibrillation Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Atrial Fibrillation Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ddhrau
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
